Core Insights - Suzhou Huaihan Medical Technology Development Co., Ltd. (Huaihan Technology) has completed a Series B financing round exclusively funded by Jiangsu Runhuai Industrial Development Fund, aimed at expanding production capacity, upgrading automation, and enhancing R&D in the biomedical materials sector [1][2] - The company, established in 2005, focuses on the research and industrialization of biomedical materials, utilizing five core technology platforms to provide efficient and safe solutions for clinical medicine [1] - The financing will support the construction of a production base for biomedical materials, including products like bio-3D printing inks and biomedical intermediates, while also accelerating automation and intelligent management processes [1] Company Overview - Huaihan Technology has demonstrated strong innovation capabilities and deep industry accumulation over the past 20 years, positioning itself as a benchmark enterprise in China's medical device sector [2] - The company’s products are widely used in surgical hemostasis, wound repair, adhesion prevention, and tissue regeneration, significantly reducing postoperative complications and improving patient recovery efficiency [1] Future Plans - Post-financing, Huaihan Technology will increase R&D investments to register new products such as bacterial cellulose artificial blood vessels and drinks, promoting the application of innovative materials in clinical medicine and the health sector [1] - The strategic partnership with Jiangsu Runhuai Industrial Development Fund aims to enhance market expansion, technological innovation, and capital empowerment, supporting Huaihan Technology in achieving new growth [2]